Intuitive Surgical, Inc. Earnings Recaps
Q2 2026
Jul 18, 2026
Shares dropped 11.2% as investors reacted negatively to signs of US procedural growth deceleration and an increasingly cautious outlook amid persistent challenges in China’s market and pricing pressures.
Key takeaways
- US da Vinci procedure growth slowed to 12%, below prior trends, with moderation mainly in deferrable procedures, linked to patient coverage and premium changes.
- China remains a challenging market due to reduced tender activity, domestic competition, and policy-driven pricing pressure.
- Global installed base expanded, with 468 da Vinci systems and 55 ION systems placed, alongside consistent 16% growth in total procedures.
- Single port (SP) procedures surged 61%, supported by adoption in Korea and the US and new product enhancements.
- Management projects cost reduction via extended use of select instruments to expand adoption, particularly in cost-sensitive markets, but these initiatives may pressure near-term margins.
Q1 2026
Apr 22, 2026
Intuitive delivered a strong Q1 2026 with 17% procedure growth driven by broad-based adoption of da Vinci and Ion systems, despite ongoing challenges in China and Japan.
Key takeaways
- Total procedures grew 17%, with da Vinci procedures up 16% to 847,000 and Ion procedures jumping 39% to 43,000, supported by increased utilization in key markets.
- U.S. da Vinci procedures advanced 14%, led by general surgery, with overall utilization growth of 4%; international procedures increased by 19%, despite headwinds in China and Japan.
- Da Vinci 5 system placements and clinical adoption remain encouraging; FDA clearance for Force Feedback instruments supports expanding digital and tactile capabilities.
- Single Port (SP) procedures surged 68%, driven by expansion in Korea, the U.S., and international markets, with upcoming product integrations poised to enhance long-term growth.
- Ion's pipeline progress includes advancements in early malignancy detection, highlighted by recent Mayo Clinic data emphasizing its role in improving lung cancer survival.
Q3 2025
Oct 22, 2025
Intuitive Surgical reported robust performance in Q3 2025, evidenced by 20% worldwide procedure growth and a 23% increase in revenue, driven by strong adoption of the da Vinci V systems.
Key takeaways
- 427 da Vinci systems placed in the quarter, with notable demand for 240 da Vinci V upgrades and strong international placements.
- Total worldwide procedure growth reached 20%, showcasing significant increases in benign general surgery and ION procedures, which surged by 52%.
- Operating discipline led to 30% earnings growth, highlighting efficiency improvements alongside revenue expansion.
- Successful regulatory clearances for new software and product features aim to enhance surgeon decision-making and patient outcomes.
- Participation in the Intuitive 360 user conference emphasized the commitment of healthcare professionals to improving surgical efficiency and outcomes.